ASCO Preview: Akeso's Ivonescimab Under Scrutiny

ASCO Preview: Akeso's Ivonescimab Under Scrutiny

As Akeso prepares for a plenary presentation at ASCO 2026, ivonescimab's HARMONi-6 overall survival data will be closely watched. This article covers key takeaways, competitive implications, and next milestones for pharma teams and investors.

Key Takeaways

• Ivonescimab’s overall survival data from the Phase III HARMONi-6 trial was selected for a plenary session at ASCO 2026, as announced by Akeso on May 27, 2026. The presentation will feature a head-to-head comparison against a PD-1 inhibitor plus chemotherapy in first-line non-small cell lung cancer.
• Over 40 studies across Akeso’s oncology pipeline will be presented at the meeting, underscoring the breadth of the company’s R&D efforts but also raising the stakes for a single, binary readout in the plenary slot.
• Pharma business development and regulatory teams should watch for partnership or acquisition interest post-ASCO and prepare for potential FDA and EMA submissions if the data are compelling. The company’s SEC filings provide additional context on trial design and financial positioning.

How Ivonescimab Secured the ASCO Plenary

On May 27, 2026, Akeso announced that ivonescimab’s HARMONi-6 overall survival data had been selected for a plenary session at the upcoming ASCO Annual Meeting. According to the company press release, more than 40 studies from Akeso’s oncology portfolio will be presented at the meeting, with the ivonescimab plenary as the headline event. The trial compared the PD-1/VEGF bispecific antibody against a standard PD-1 inhibitor backbone, a rigorous design that raises the bar for evidence generation in first-line NSCLC.

The plenary slot is reserved for studies deemed practice-changing by ASCO’s selection committee. Only a handful of late-stage trials receive this placement each year, making it a powerful catalyst for company valuation. The HARMONi-6 data have been previously disclosed in Akeso’s recent SEC filing, which also outlines the trial’s design and primary endpoints. A separate 2025 annual filing from Summit Therapeutics, Akeso’s partner for ex-China rights, provides additional details on the collaboration structure and financial milestones.

What Do the HARMONi-6 Data Mean for Pharma Teams?

For business development teams, the ASCO readout creates a narrow window for decision-making. If ivonescimab confirms a clinically meaningful overall survival benefit, it could disrupt the current PD-1/PD-L1 duopoly in first-line NSCLC, where Keytruda and Opdivo generate billions annually. A bispecific that simultaneously blocks PD-1 and VEGF may offer a differentiation point that payers and clinicians find compelling. Companies developing competing bispecifics or novel combination regimens will need to reassess their timelines and positioning. Akeso might attract partnership overtures from large pharma looking to replace aging PD-1 franchises, or Summit Therapeutics could become a takeout target. The S-3 registration statement filed by Summit in 2022 provides baseline information on the partnership’s economic terms.

Regulatory teams should note that overall survival remains the gold standard for approval in the curative or early-line setting, as emphasized in FDA and EMA guidance documents. While Akeso has not yet disclosed specific submission timelines, the ASCO plenary is widely seen as a prelude to regulatory filings in the U.S. and EU. If the data package includes a clean safety profile, an expedited review pathway is plausible given the high unmet need in advanced NSCLC. The plenary presentation will also include a formal discussant who may highlight strengths or limitations, such as the geographic scope of the trial — predominantly Chinese sites — and whether the results generalize to Western populations.

Investors must prepare for binary outcomes. A positive readout could drive a significant revaluation of Akeso and Summit shares, while any signal of unusual toxicity or a less durable benefit could reset expectations. In the days after the presentation, pharma analysts will circulate detailed notes, so internal competitive intelligence teams should have rapid-response plans ready.

What Are the Next Scientific and Commercial Hurdles?

Beyond the ASCO spotlight, ivonescimab faces several challenges that will determine its ultimate market potential. First, regulators will require confirmatory evidence in Western populations — the current HARMONi-6 dataset comes largely from Chinese sites, and both the SEC filings and company disclosures reference ongoing global expansion trials. Second, manufacturing scale-up and supply chain logistics must be addressed; Akeso has not yet disclosed commercial-scale capacity for ivonescimab. Third, pricing and reimbursement negotiations will be critical, especially if payers demand a discount versus entrenched PD-1 inhibitors that face emerging biosimilar competition. Business development teams should track these elements in parallel with the clinical readout.

Another factor to watch is the safety profile. PD-1/VEGF bispecifics carry theoretical risks of immune-related adverse events and antiangiogenic toxicities such as hypertension and bleeding. The HARMONi-6 presentation will need to show that ivonescimab’s benefit-risk profile is acceptable, particularly if the OS gain comes with a higher rate of grade 3 or higher adverse events. Companies developing similar mechanisms will be parsing the data for any signal that could inform their own development programs.

Frequently Asked Questions

Related profiles

• ivonescimab
• Akeso

Related coverage

• Precision under pressure: logistics facts shaping nuclear medicine scalability
• Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
• Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4)